Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%

NCT07450183 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.

NCT NCT07450183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07450183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Lead sponsor
Henry Ford Health System
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 1, 2027
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc)